Reduced neutralizing antibody production against Omicron XBB.1.5 in people living with HIV  

作　　者：Jiaying Zhang Jiming Yin Wenjing Wang Juanli Gao Tongzeng Li Danlei Mou Lianchun Liang Qinghua Meng Yingmei Feng 

机构地区：[1]Department of Infectious Diseases,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China [2]Beijing Institute of Hepatology,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China [3]Department of Medical Oncology,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China [4]Department of Science and Development,Beijing Youan Hospital,Capital Medical University,Beijing 100069,China

出　　处：《Chinese Medical Journal》2024年第21期2633-2635,共3页中华医学杂志(英文版)

基　　金：supported by a grant from the National Key R&D Program of China(No.2023YFC0872400).

摘　　要：To the Editor:The emergence of Omicron has gained global attention since November 2021.Of the Omicron strains,Omicron XBB.1.5 is the most recently identified.It carries deletions and more than 30 mutations,which have modified the biological features of severe acute respiratory syndrome coronavirus-2(SARS-CoV-2)for enhanced transmissibility and immune escape capacity.

关 键 词：capacity gained NEUTRAL 

分 类 号：F42[经济管理—产业经济]